News & Events

Discover the events, collaborations, achievements and milestones that have helped shape iSARP and contributed to the growth and impact of our research program throughout the year.

Annual Reports

iSARP Annual Reports

2025

2024

Kurt

Congratulations to Kurt Hildebrand!

Congratulations to iSARP trainee Kurt Hildebrand on successfully defending his PhD thesis under the supervision of Dr. Michael Monument! A remarkable academic achievement and an exciting milestone in his research journey.


Alex

Alex Iwasyk Awarded CIHR Canada Graduate Scholarship

Congratulations to iSARP MSc student Alex Iwasyk, supervised by Dr. Joe Kendal, on receiving the prestigious CIHR Canada Graduate Master’s Scholarship! A wonderful recognition of his academic excellence and research potential.


Holash

ACTIVATION Health: Made-at-UCalgary app aims to change how recovery is measured

Faculty of Kinesiology and Cumming School of Medicine researchers transform a shared clinical challenge into a digital health solution with growing research impact


Changing the narrative.

Positioning Calgary at the Forefront of Sarcoma Research

Through the support of grants and donors, Dr. Michael Monument rewrites Calgary’s role in identifying new therapies to treat sarcoma.


Joe

Hockey, Hope, and the Fight Against Cancer

Meet Drs. Joe Kendal, MD, and Michael Monument, MD, orthopedic surgeons and researchers who are lined up to play in the 2026 Stick it to Cancer charity hockey


Stick it To cancer

Stick IT To Cancer Charity Hockey Game

The 2026 Stick It to Cancer charity hockey event brought physicians, students, and the community together for a memorable evening, surpassing its $150,000 fundraising goal and raising an incredible $166,420


research

Precision target discovery in high-risk soft tissue sarcoma

Cancer Types - Sarcoma

Funding Program - MOHCCN Gold Cohort - Regional Consortium Projects

Regional Consortiums - Prairie Cancer Consortium

Locations - Alberta

Partners

iSARP Clinical Trials

Enhancing clinical trial access for Alberta sarcoma patients remains a cornerstone of iSARP's mandate. Led by Drs. Khan and Feng, iSARP continues to see year-over-year expansion of clinical trials openings for sarcoma and related musculoskeletal neoplasms. iSARP also continues to strengthen its role within CanSaRCC, contributing high-quality clinical and outcomes data into this national sarcoma consortium.


CHONQUER Study

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen. Calgary is a participating centre.

CarboStar

phase II, randomized, openlabel study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.

SRC8

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas. Calgary is a participating centre.

INSIGHT

An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib.

REPAIR

Multi-centre study evaluating functional recovery after surgical intervention for lowerextremity metastatic bone disease using PROMIS®. Calgary is a participating centre; iSARP manages enrollment and data reporting.

PERFORM

Evaluates the effect of resection and reconstruction versus internal fixation on patient-important outcomes in metastatic proximal femur disease. Calgary is a participating centre; iSARP manages enrollment and data reporting.

ACTIVATION

Investigates PROMIS® patient-reported outcome and mobility in sarcoma and metastatic bone disease patients using a smartphone application to capture realworld activity data. Calgary is the coordinating centre.

TANGENT

A global Phase 3 clinical trial evaluating emactuzumab for patients with unresectable Tenosynovial Giant Cell Tumor (TGCT).